Clinical evaluation of anti-inflammatory and analgesic activities of AQUATURM® (branded extract of Curcuma longa) in individuals diagnosed with osteoarthritis– A randomized, double blind, placebo controlled clinical study
DOI:
https://doi.org/10.53555/ans.v9i1.2405Keywords:
AQUATURM®, Osteoarthritis, Curcumin, knee joint pain, inflammation, turmeric, supplement, pain, anti-inflammatoryAbstract
Background: Anti-inflammatory and analgesic activities of Curcuma longa extract can support in the management of
knee joint pain caused by osteoarthritis.
Objectives: Evaluation of anti-inflammatory and analgesic activities of AQUATURM® (branded extract of Curcuma
longa) in individuals diagnosed with knee joint pain caused by osteoarthritis.
Methods: 60 participants diagnosed with knee osteoarthritis were randomized in two groups through a double-blinded
procedure. Of these, 56 subjects completed the study (26 in AQUATURM® group and 30 in placebo group).
AQUATURM® or its matching placebo was given in a dose of 1 capsule of 250 mg twice daily after meals for 90 days.
Assessment of comparative change in knee joint pain on VAS, and WOMAC Index was performed in monthly intervals.
Other parameters included time to walk 50 feet, use of painkillers as rescue medication, changes in the CRP levels, and
safety assessment through adverse event monitoring and laboratory parameters was performed.
Results: A significant reduction (p<0.05) in pain was observed on the VAS scale with the use of AQUATURM® (55.77
±15.98 to 46.38 ±16.17) as compared to placebo (56.67 ±17.02 to 50.93 ±14.88) over a period of 90 days. On the WOMAC
index, a significant reduction (p<0.05) was observed on the domains of pain (10.92±3.37 to 7.73 ±3.59 in AQUATURM®
group and 10.90 ±3.16 to 9.76 ±3.81 in placebo group) and stiffness (4.80 ±1.60 to 2.88 ±1.58 in AQUATURM® group
and 4.50 ±1.43 to 4.36 ±2.00 in placebo group). A significant reduction was observed on CRP levels (4.97 ±1.59 to 2.68
±0.88 with AQUATURM® and 4.93 ±1.99 to 4.19 ±2.81 with placebo). AQUATURM® did not produce any significant
adverse effects on clinical and laboratory parameters. AQUATURM® was well tolerated.
Conclusion: Supplementation of AQUATURM® in individuals diagnosed with knee osteoarthritis showed significant
reduction in pain, stiffness and swelling showing its analgesic and anti-inflammatory effect
Downloads
References
Hangerman D.; N. Engl. J. Med: 320:1322.1989.
Hochberg MC, Altman RD et al Guidelines for the medical management of osteoarthritis. Part
I.; Arthritis Rheum. 1995 Nov; 38(11):1535-40.
Maria Jose Alcaraz, et al, New molecular targets for the treatment of osteoarthritis.
Biochemical Pharmacology 80 (2010) 13–21
Felson DT, Laurence RC, Diepee Pa et al; Ann. Intern. Med; 133(9); 726-737; 2000
Chopra A, Goregaonkar AB, Maroli S et al; Randomized double blind study to document
Efficacy and Safety of Refecoxib + Betacyclodextrin complex in comparison with Rofecoxib in
Patients suffering from Osteoarthritis; Ind. Med. Gazette 180-196; May 2002.
Erlangga Yusuf, Pharmacologic and Non-Pharmacologic Treatment of Osteoarthritis, Current
Treatment Options in Rheumatology, Volume 2, Pages 1110125 (2016)
McAlindon TE, et al, Glucosamine and chondroitin for treatment of osteoarthritis. A
systematic quality assessment and meta-analysis, JAMA 2000;283:1469-75.
Evans JM, McMahon AD, et al. Topical non-steroidal anti-inflammatory drugs, and admission
to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control
study. BMJ 1995;311:22-6.
Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications
related to use of non-steroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;
:787-96.
Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular
events and celecoxib: a systematic review and meta-analysis. J R Soc Med 2006; 99:132-40.
Hermann M, Ruschitzka F. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional
non-steroidal anti-inflammatory drugs. Ann Med 2007;39:18-27.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of
atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-8.
Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, et al. Temporal
relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular
risk. Drug Saf 2006; 29:621-32.
Aithal GP, Day CP. Non-steroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver
Dis 2007;11:563-75, vi-vii.
Hochberg MC, Altman RD et al Guidelines for the medical management of osteoarthritis. Part
II. Osteoarthritis of the knee. American College of Rheumatology.; Arthritis Rheum. 1995 Nov;
(11):1531-6.
Asher GN, Spelman K. Clinical utility of curcumin extract. Altern Ther Health
Med. 2013;19(2):20–2.
Zhuo Zhang, et. al. Curcumin slows osteoarthritis progression and relieves osteoarthritisassociated pain symptoms in a post-traumatic osteoarthritis mouse model. Arthritis Res Ther.
; 18: 128.
Marina Cristina Akuri, Sandra Maria Barbalho, Raíssa Meira Val, and Elen Landgraf
Guiguer. Reflections about Osteoarthritis and Curcuma longa. Pharmacogn Rev. 2017 Jan-Jun;
(21): 8–12
G F Ibironke, I O Owemidu. Analgesic activity of the ethanol extract of Curcuma longa
rhizome and its mechanism of action. Niger J Physiol Sci. 2014 Jun 19;29(1):67-70.
Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity
for the treatment of osteoarthritis: curcumin for osteoarthritis management. Springer
plus. 2013;2(1):56. doi: 10.1186/2193-1801-2-56.
Vasavda Krup, Hedge Prakash L and Harini A. Pharmacological Activities of Turmeric
(Curcuma longa linn): A Review. J Homeop Ayurv Med 2013, 2:4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal For Research In Applied And Natural Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
In consideration of the journal, Green Publication taking action in reviewing and editing our manuscript, the authors undersigned hereby transfer, assign, or otherwise convey all copyright ownership to the Editorial Office of the Green Publication in the event that such work is published in the journal. Such conveyance covers any product that may derive from the published journal, whether print or electronic. Green Publication shall have the right to register copyright to the Article in its name as claimant, whether separately
or as part of the journal issue or other medium in which the Article is included.
By signing this Agreement, the author(s), and in the case of a Work Made For Hire, the employer, jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere, and is not being considered for publication elsewhere in any form, except as provided herein. Each author’s signature should appear below. The signing author(s) (and, in
